Navigation Links
Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
Date:10/14/2008

continued throughout the study period.

Two patients in each treatment arm experienced criterion increases in intraocular pressure (defined as a pressure of greater than or equal to 21 mmHg and a change from baseline greater than or equal to 10mmHg at the same visit). Another important safety finding was the number of patients withdrawn from the study due to lack of efficacy. In the Pred Forte group, 12.5% of patients were withdrawn from the study, while no Durezol patients were withdrawn from the study for these reasons. This difference was significant, P=0.01.

The results from this study will be combined with data from previous trials conducted in Japan to support a supplemental New Drug Application for anterior uveitis. "The results of these trials are truly exciting," noted Barry Butler, CEO and President of Sirion Therapeutics. "Although this study was not designed to detect the statistical superiority of one drug over the other, the consistent numerical advantage of Durezol across all endpoints is impressive. This is especially so, when you consider that Pred Forte has 20 times the concentration of Durezol and was dosed twice as often. This clearly demonstrates the potency of Durezol."

About Uveitis

Uveitis is inflammation of the middle three layers of the eye: iris, choroid, and ciliary body. In the US it is responsible for an estimated 30,000 new cases of legal blindness each year and up to 15% of all cases of blindness. It affects 0.2% of the population in industrial nations, with as much as 10 times that prevalence in the undeveloped world. The most common form of the condition is anterior uveitis, associated primarily with inflammation of the iris. If left untreated, uveitis can cause permanent damage and vision loss due to the development of glaucoma, cataract, or retinal edema. In addition to causing blindness, the severe pain and photophobia that accompany anterior uveitis can be debilitating.

About Durezol

Dur
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
2. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... July 10, 2014   LabStyle Innovations Corp ... today announced the appointment of Professor Richard ... its Board of Directors. Prof. Stone ... experience to LabStyle as an entrepreneur, venture capitalist ... corporate governance expert. He currently serves on the ...
(Date:1/15/2014)... Jan. 15, 2014 Most osteoporosis patients want a ... recent online survey* sponsored by Mission Pharmacal Company. The ... Osteoporosis Foundation online support community, revealed that 74 percent ... comes in a form other than a pill or ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Intravenous to Subcutaneous Conversion -, SAN ... HALO ), a biopharmaceutical company developing ... new pre-clinical findings on the local tolerability ... the American,Association for Cancer Research (AACR) conference., ...
... for Novavax,s ... Influenza Vaccine Candidate, ROCKVILLE, Md., April 16 Novavax, ... positive results from an,immunogenicity study in ferrets inoculated with the ... to,complete its planned investigational new drug ("IND") application to,support initiation ...
Cached Medicine Technology:Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference 2Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference 3Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference 4Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 2Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 3
(Date:7/12/2014)... you make exercise fun, you,ll eat less after your workout, ... led on a 1.4-mile walk and were either told it ... participants were given lunch after the walk, and those who ... more chocolate pudding for dessert than those who were told ... adults were given mid-afternoon snacks after their walk. Those who ...
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... recent article released by Seattle's well known plastic surgeon, Dr. ... cosmetic surgical procedures in summer months . , ... to enliven the rainy Pacific Northwest, many people are turning ... work out as much during the winter as they had ... people eager to look their best for their summer vacations, ...
(Date:7/12/2014)... 12, 2014 Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
Breaking Medicine News(10 mins):Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2
... College London have developed a new technology that allows ... human skeleton// . This is done without any risk ... clinical trials as promising. ,The technique called ... titanium rod attached directly to the bone. The artificial ...
... The Victorian Burden of Disease reports that the Central Goldfields ... and women//. The study was conducted by the Human Services ... injuries in Victoria. ,The study looks into the harmful effects ... poor diet. The eastern part of Melbourne is reported to ...
... method has been discovered by two scientists Vivian Cheung ... study //medical disorders that are recessively inherited. ... differ significantly and this new diagnostic tool was found ... genome-wide expression profiles. ,As a model for ...
... published in the International Journal of Radiation Oncology, no ... irradiation and the development of rectal cancer. ... Radiation Oncology at the Ottawa Hospital Regional Cancer Centre ... facts and helped people choosing radiation therapy as one ...
... The parliamentary consultative committee Sunday said medicines sold in ... taxes from Oct 2. ,The decision was taken ... to the ministry of chemicals, fertilizers and steel. The ... ,The members decided that the 354 drugs ...
... Rochester when investigating for an alternative menopausal treatment have ... as estrogen. ,Gabapentin, a seizure drug lowered ... and out of the cells, which helped in lowering ... who have been investigating new therapies for hot flashes ...
Cached Medicine News:Health News:New Diagnostic Tool Uncovered Gene Expression Patterns in Recessive Genetic Disorders 2Health News:Research Finds Lesser Rectal Cancer Risks Associated with Prostatic Irradiation 2Health News:Gabapentin Reduced Menopausal Symptoms as Estrogen – Study Find 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: